Snowflake announced on the day of the report that its fiscal second-quarter adjusted earnings were 62 cents per share, beating the 45-cent estimate, and that revenue reached $1.55 billion, up 35% year over year, with product revenue up 37% to $1.49 billion, leading its shares to jump more than 23% in premarket trading. ^[1] Ultragenyx announced that its drug apazunersen failed to meet the primary goal in a late-stage trial for Angelman syndrome, showing no meaningful improvement in cognitive ability compared with placebo, and its shares plunged over 44% in premarket trading; the company said it is reviewing the future of the program. ^[2] According to HPE, an unauthenticated attacker could exploit the critical flaws by sending crafted packets to the vulnerable service, achieving remote code execution with elevated privileges. ^[3] HPE's advisory says the updates also resolve 22 high-severity CVEs and 11 medium-severity CVEs, with potential impacts including denial-of-service, remote code execution, arbitrary command execution, arbitrary script code execution in a victim's browser, authentication bypass, privilege escalation, information disclosure, access controls bypass, and arbitrary file reads. ^[4][8] Nearly two dozen issues, tracked collectively as CVE-2026-73749 with a CVSS score of 9.8, were addressed with the updates, according to HPE. ^[5] In pre-open trading on the day this article was published, Hewlett Packard Enterprise (HPE) stock fell 5.6% to $48.93, reflecting a mixed post-earnings reaction. ^[6] Snowflake raised its fiscal 2027 product revenue guidance to $6.07 billion from its prior forecast of $5.84 billion, after posting a third straight quarter of accelerating product revenue growth. ^[7]